Latest News

(UroToday.com) The Earlier Treatment in Prostate Cancer “How can we maximize the therapeutic index?” educational session at the European Society of Medical Oncology’s (ESMO) 2021 congress included a presentation by Nicolas Mottet discussing evidence-based treatment options in biochemically relapsed prostate cancer. Dr. Mottet notes that the definition of relapse after external beam radiotherapy is the nadir […]

Arnhem (The Netherlands), 20 September 2021. Although urinary incontinence (UI) is a very common issue affecting 10% to 20% of people across Europe1, it is still very much a taboo. This is revealed by a new survey2 commissioned by the European Association of Urology (EAU). Of the people that experience some form of UI, nearly […]

(UroToday.com) The Realizing Potential Combination and Personalized Therapy educational session at the European Society of Medical Oncology’s (ESMO) 2021 congress included a presentation by Dr. Cristina Suarez discussing the future targets and combinations for metastatic RCC. These unique combinations include alternative proangiogenic pathways, immunotherapies/enhancing immune checkpoint inhibitors, metabolic pathways, and PARP inhibitors.

(UroToday.com) The Realizing Potential Combination and Personalized Therapy educational session at the European Society of Medical Oncology’s (ESMO) 2021 congress included a presentation by Dr. Manuela Schmidinger discussing the current status of personalized therapy in metastatic RCC. Dr. Schmidinger notes that the reason we need personalized therapy in metastatic RCC is that there are currently four […]

(UroToday.com) The 2021 European Society of Medical Oncology’s (EMSO) annual congress included a proffered paper session in non-prostate genitourinary tumors, as well as a discussant presentation by Dr. Christian Kollmannsberger discussing decreasing morbidity for the treatment of stage II seminoma. The abstract discussed was “Single-dose carboplatin followed by involved-node radiotherapy as a curative treatment for seminoma […]

Alicia Morgans: Hi, my name is Alicia Morgans and I am a GU Medical Oncologist at Dana-Farber Cancer Institute in Boston in the US. I am so excited to have here with me today, Dr. Karim Fizazi, who is a GU Medical Oncologist, as well as being a Professor of Oncology at the University of […]

(UroToday.com) The Realizing Potential Combination and Personalized Therapy educational session at the European Society for Medical Oncology (ESMO) 2021 congress included a presentation by Dr. Toni Choueiri discussing whether there is an optimal first-line combination approach for metastatic renal cell carcinoma (RCC). The current first-line combination therapies that are FDA approved are listed as follows:

Profile: Prof. Jens Sønksen succeeds Prof. Manfred Wirth as EAU treasurer   Prof. Jens Sønksen (DK) has a long history at the EAU. A member since 1996, he was part of the Scientific Congress Office from 2012 to 2017 and has served as Adjunct Secretary General – Clinical Practice since 2017. When the executive board, in […]

Alicia Morgans: Hi, my name is Alicia Morgans and I’m GU Medical Oncologist at Dana-Farber Cancer Institute in Boston. I am so excited to have here with me today, Dr. Bertrand Tombal, who is a Professor and Chair of Urology at The Université Catholique de Louvain in Brussels, Belgium. Thank you so much for being […]

The medical and surgical management of kidney stones is one of the most common functions of the urologist. Management choices are often nuanced, involving the decision to embark on one surgical plan among several options.